Nintedanib and Symptoms of Fibrotic Lung Disease: a Glimmer of Hope for Patients Living with Pulmonary Fibrosis
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M
. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92.
DOI: 10.1056/NEJMoa1402582.
View
2.
Raghu G, Remy-Jardin M, Richeldi L, Thomson C, Inoue Y, Johkoh T
. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022; 205(9):e18-e47.
PMC: 9851481.
DOI: 10.1164/rccm.202202-0399ST.
View
3.
Noble P, Albera C, Bradford W, Costabel U, Glassberg M, Kardatzke D
. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779):1760-9.
DOI: 10.1016/S0140-6736(11)60405-4.
View
4.
Swigris J, Andrae D, Churney T, Johnson N, Scholand M, White E
. Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. Am J Respir Crit Care Med. 2020; 202(12):1689-1697.
PMC: 7737580.
DOI: 10.1164/rccm.202002-0415OC.
View
5.
Swigris J, Esser D, Wilson H, Conoscenti C, Schmidt H, Stansen W
. Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017; 49(1).
DOI: 10.1183/13993003.01788-2016.
View